A growing volume of patients are engaged with their medical treatment plans. Additionally, patients feel empowered by the amount of health information available online and on apps, and by the wide range of wearables. In this environment, digitally enabled ‘beyond the pill’ solutions are becoming critical. These solutions help increase the adherence to treatment and outcomes, and they generate the data that pharma companies need to demonstrate drug efficacity.
Pharma companies recognize the disruptive potential and are investigating a wide range of digital initiatives. Although, many find it hard to determine what initiatives to scale up and how to do this, as they are still unclear what digital success will look like five years from now. Therefore, pharma companies will have to build the capabilities to anticipate or react rapidly to these digital innovations.
Most pharma companies have started to shape some digital capabilities, but talent and resources for their efforts can be incoherent. Clear strategic direction and solid sponsorship is key to secure the funding and human resources required to reach a viable scale. At Modis we have experts working towards sustainability in IMI projects, this expertise can be used to guide pharma companies through these hurdles towards digital success. In addition, talent and partnerships are critical in this digitalization and companies are often unclear about what kinds of partnerships to set up and how to extract value from them.
Source: McKinsey & Company, Digital Marketing Institute